Skip to main content
Log in

In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The relationship between the daily oral dose of the benzamide amisulpride and the striatal D2-dopamine receptors occupancy was investigated in 11 schizophrenic patients using positron emission tomography with76Br-bromolisuride. The patients were studied before and during chronic treatment with amisulpride over a wide range of doses. The test-retest variability of the method was estimated to be 5.8% in a group of four patients receiving placebo. A curvilinear relationship was demonstrated between the amisulpride doses and the D2-receptor occupancy. A range of 70–80% occupancy of the striatal D2 receptors, suggested as an optimal interval for therapeutic action on positive psychotic symptoms, was obtained with doses of amisulpride ranging between 630 and 910 mg per day, while an occupancy of 85%, suggested to be associated with pronounced extrapyramidal side-effects, was reached with 1100 mg per day.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andreasen NC (1987) L'utilisation de la SANS et de la SAPS. Psychiatr Psychobiol 2:412

    Google Scholar 

  • Baron JC, Maziere B, Loc'h C, Cambon H, Sgouropoulos P, Bonnet AM, Agid Y (1986) Loss of striatal76Br-bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. J Cereb Blood Flow Metab 6:131–136

    Google Scholar 

  • Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99:463–472

    Google Scholar 

  • Boyer P, Lecrubier Y, Puech AJ (1990) Treatment of positive and negative symptoms: pharmacological approaches. In: Andreasen NC (ed) Schizophrenia: positive and negative symptoms and syndromes. Modern Problems in Pharmacopsychiatry. Karger, Basel, 24:152–174

    Google Scholar 

  • Burt Dr, Creese I, Snyder SH (1977) Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196:326–328

    Google Scholar 

  • Cambon H, Baron JC, Boulenger JP, Loc'h C, Zarifian E, Maziere B (1987) In vivo assay for neuroleptic receptor binding in the striatum. Positron tomography in humans. Br J Psychiatry 151:824–830

    Google Scholar 

  • Carnoy P, Ravard S, Wemerman B, Soubrie P, Simon P (1986) Behavioral deficit induced by low doses of apomorphine in rats; evidence for a motivational and cognitive dysfunction which discriminates among neuroleptics. Pharmacol Biochem Behav 25:503–509

    Google Scholar 

  • Costa e Silva JA (1989) Comparative double-blind study of amisulpride versus haloperidol in the treatment of acute psychotic states. In: Borenstein P, Boyer P, Braconnier A et al. (eds) Amisulpride. Expansion Scientifique Française, Paris, pp 93–104

    Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481–483

    Google Scholar 

  • Delforge J, Loc'h C, Hantraye P, Stulzaft O, Khalili-Varasteh M, Maziere M, Syrota A, Maziere B (1991) Kinetic analysis of central (76Br)bromolisuride to D2 dopamine receptors studied by PET: J Cereb Blood Flow Metab 11:914–925

    Google Scholar 

  • Delcker A, Schoon ML, Oczkowski B, Guertner HJ (1990) Amisulpride versus haloperidol in treatment of schizophrenic patients — results of a double-blind study. Pharmacopsychiatry 23:125–130

    Google Scholar 

  • Dufour A, Desanti C (1989) Pharmacokinetics and metabolism of amisulpride. In: Borenstein P, Boyer P, Braconnier A et al. (eds) Amisulpride. Expansion Scientifique Française, Paris, pp 43–51

    Google Scholar 

  • Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71–76

    Google Scholar 

  • Farde L, Nordström A-L, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544

    Google Scholar 

  • Farde L, Nordström AL, Karlsson P, Halldin C, Sedvall G (1995) Positron emission tomography studies on dopamine receptors in schizophrenia. Clin Neuropharmacol 18 [suppl 1]:S121-S129

    Google Scholar 

  • Guyon A, Abouly-Besse F, Biala Z, Puech AJ, Thiebot MH (1993) Potentiation by low doses of selected neuroleptics of food-induced place preference in rats. Psychopharmacology 110:460–466

    Google Scholar 

  • Hillert A, Philip M, Gattaz WF, Sauer H, Adler G, Wetzel H, Benkert O (1994) Amisulpride vs flupentixol in the treatment of schizophrenia with predominant positive symptomatology. Neuropsychopharmacology 10:31S

  • Kornhuber J, Riederer P, Reynolds GP, Beckmann H, Jellinger K, Gabriel E (1989)3H-Spiperone binding sites in post-mortem brains from schizophrenic patients: relationships to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm 75:1–10

    Google Scholar 

  • Martinot JL, Paillere-Martinot ML, Loc'h C, Peron-Magnan P, Mazoyer B, Lecrubier Y, Hardy P, Beaufils B, Allilaire JF, Maziere B, Slama MF, Syrota A (1990) Central D2 receptor blockade and antipsychotic effects of neuroleptics. Preliminary study. Psychiatr Psychobiol 5:231–240

    Google Scholar 

  • Martinot JL, Paillere-Martinot ML, Loc'h C, Hardy P, Poirier MF, Mazoyer B, Beaufils B, Maziere B, Allilaire JF, Syrota A (1991) The estimated density of D2 striatal receptors in schizophrenia. A study with positron emission tomography and76Br-bromolisuride. Br J Psychiatry 158:346–350

    Google Scholar 

  • Maziere B, Loc'h C, Baron JC, Sgouropoulos P, Duquesnoy N, D'Antona R, Cambon H (1985) In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and 76 Br-bromospiperone. Eur J Pharmacol 114:267–272

    Google Scholar 

  • Maziere B, Loc'h C, Stulzaft O, Hantraye P, Ottaviani M, Comard D, Maziere M (1986) (76Br)bromolisuride: a new tool for quantitative in vivo imaging of D2 dopamine receptors. Eur J Pharmacol 127:239–247

    Google Scholar 

  • Maziere B, Loc'h C, Stulzaft O, Martinot JL, Syrota A, Maziere M (1990) PET imaging of D2 receptors in the living baboon and human brain in normal and pathological conditions using76Br-bromolisuride. In: Bunney WE, Hippius H, Laakmann G, Schmauss M (eds) Neuropsychopharmacology. Springer, Heidelberg, pp 409–417

    Google Scholar 

  • Nordström AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993) Central D2-dopamine occupancy in relation to antipsychotic drug effect: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227–235

    Google Scholar 

  • Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152:130–133

    Google Scholar 

  • Puech AJ, Simon P, Boissier JR (1978) Benzamides and classical neuroleptics: comparison of their actions using 6 apomorphine-induced effects. Eur J Pharmacol 50:291–300

    Google Scholar 

  • Scatton B, Perrault G, Sanger DJ, Schoemaker H, Carter C, Fage D, Gognon F, Chergui K, Cudennec A, Benavides J (1994) Pharmacological profile of amisulpride, an atypical neuroleptic which preferentially blocks presynaptic D2/D3 receptors. Neuropsychopharmacology 10:242S

  • Scatton B, Perrault G, Gonon R, Depoortere R, Sanger D, Schoemaker H (1995) Novel neuroleptics acting on presynaptic dopaminergic receptors. Neuropsychopharmacology 5:213S

    Google Scholar 

  • Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146–151

    Google Scholar 

  • Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shive CY, Cooper TB, Brodie JD (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146:905–908

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martinot, J.L., Dao-Castellana, M.H., Loc'h, C. et al. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology 124, 154–158 (1996). https://doi.org/10.1007/BF02245616

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02245616

Key words

Navigation